Pipeline overview | Innate Pharma

Our commitment to patients

Innate Pharma is developing an innovative pipeline of antibody-based therapeutics by leveraging the body’s immune system to improve outcomes for patients suffering from cancer and other life-threatening diseases.

The immune system plays a critical role in many diseases and offers unique opportunities to find meaningful solutions for patients with complex and underserved diseases. We are committed to translating groundbreaking scientific insights in immune biology into new immunotherapies that improve patient outcomes, extend lives and give new hope to patients who have no other options.

Key assets in clinical development:

Lacutamab

KIR3DL2

Proprietary program

Cutaneous T Cell Lymphoma (Sézary Syndrome / Mycosis Fungoides)

Phase 2 / TELLOMAK / Innate Pharma clinicaltrials.gov

Peripheral T Cell Lymphoma

Phase 2 / KILT / LYSARC clinicaltrials.gov

IPH4502

Nectin-4

Proprietary program

Advanced Solid Tumors

Phase 1 / Innate Pharma clinicaltrials.gov

Monalizumab

NKG2A

Co-development with AstraZeneca

Unresectable Stage III Non-small Cell Lung Cancer

Phase 3 / PACIFIC-9 / AstraZeneca clinicaltrials.gov

Neoadjuvant NSCLC, other

Phase 2 / NeoCOAST-2 / AstraZeneca clinicaltrials.gov

IPH6501

CD20, 2nd generation ANKET®

Cancer

Phase 1/2 / IPH6501-101 / Innate Pharma clinicaltrials.gov

IPH6101

CD123, trifunctional ANKET®

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High Risk-myelodysplasia

Phase 1/2 / Innate Pharma clinicaltrials.gov

IPH6401 (SAR'514)

BCMA, trifunctional ANKET®

Partnered with Sanofi

Multiple Myeloma

Phase 1/2 / Sanofi clinicaltrials.gov

IPH5201

CD39

Partnered with AstraZeneca

Neoadjuvant Non-small Cell Lung Cancer

Phase 2 / MATISSE / Innate Pharma clinicaltrials.gov

IPH5301

CD73

Proprietary program

Cancer (Solid Tumors)

Phase 1 / CHANCES / Institut Paoli-Calmettes clinicaltrials.gov

What are clinical trials?

Clinical trials are essential to advance new therapies and provide opportunities to patients with unmet medical needs to have access to potential new medicines before they reach the market.

A clinical trial involves research participants. It follows a pre-defined plan or protocol to evaluate the effects of a potential new medicine on health outcomes. By taking part in clinical trials, participants not only play a more active role in their own health care, but they also can access experimental treatments and help others by contributing to medical research.

What are the different phases of clinical trials?

Clinical trials are usually described based on their Phase: Phase 1, 2 and 3. This classification is used by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as well as other regulatory agencies to determine if the drug can be approved for use.

Each of these clinical phases is described below.

A Phase 1 trial tests an experimental treatment on a small group of healthy people (20 to 80) to judge its safety and side effects and to find the correct drug dosage. In the case of some products for severe or life-threatening diseases, such as cancer, the initial human testing is often conducted in patients.
A Phase 2 trial uses more people (100 to 300). This phase aims to preliminary evaluate the efficacy of an experimental drug in patients who have a certain disease or condition. These trials also continue to study safety, including short-term side effects. This phase can last several years.
A Phase 3 trial are undertaken to further evaluate safety and clinical efficacy, studying different populations and different dosages, using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to about 3,000 people. An experimental drug could be approved for clinical use by regulatory agencies based on the results of a Phase 3 trial or in some instances on earlier phase studies.
Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the applicable regulator may mandate the performance of Phase 4 clinical trials as a condition of approval.

In specific situations, certain phases of development can be merged or even skipped when clear signs of efficacy emerge in the early phases of development and the potential new treatment is designed for patients with major unmet medical needs. However, these deviations from the standard pattern of development must be discussed and approved by health authorities.

What are the benefits and risks of clinical trials?

The following list of possible benefits and risks is not exhaustive. The informed consent form of a clinical study would specify the possible benefits and risks of that particular clinical study.

Possible Benefits

Gaining access to innovative, new, investigational medicines that may not be available outside of the clinical study setting
Helping to make a difference in the lives of others affected by the same disease or condition

Possible Risks

Increasing demand for your time due to the potential for more visits to the clinical study site, hospital, or treatment center
Experiencing side effects from the study medication or study procedures, which may range from minor to serious or life-threatening

As with any decision that affects your health, it’s important to discuss the benefits and risks of clinical study participation with your physician. Although the decision of whether or not to participate is ultimately yours, it’s important to make sure that you understand everything that is involved. Talk with your oncologist, your family, healthcare professionals. Ask questions and discuss your concerns.

Who can participate in a clinical trial and how?

To participate in a clinical trial, patients must meet specific eligibility criteria. These criteria help researchers identify appropriate candidates for participation and are designed to promote safety and accuracy of study results. The criteria may allow or prevent participation.
Patients should discuss this with their physician and oncologist if they wish to be included in a clinical trial.

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers